cetuximab

Open Access
Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer
MOTOYUKI SUZUKI, YUKINORI TAKENAKA, TOSHIHIRO KISHIKAWA, YOSHIFUMI YAMAMOTO, ATSUSHI HANAMOTO, YOICHIRO TOMIYAMA, TAKAHITO FUKUSUMI, TAKAHIRO MICHIBA, NORIHIKO TAKEMOTO, SUSUMU NAKAHARA and HIDENORI INOHARA

Anticancer Research April 2021, 41 (4) 2045-2051; DOI: https://doi.org/10.21873/anticanres.14973
You have access
Effects of Type of Antibody to EGFR and Hypomagnesemia on Overall Survival in First-line Treatment of Patients With Unresectable Advanced/Recurrent Colorectal Cancer
MICHIO KIMURA, EISEKI USAMI and TOMOAKI YOSHIMURA

Anticancer Research December 2020, 40 (12) 7135-7140; DOI: https://doi.org/10.21873/anticanres.14743
You have access
Comparison Between Biweekly and Weekly Cetuximab in Patients With Metastatic Colorectal Cancer: A Meta-analysis
AKIHISA MATSUDA, TAKESHI YAMADA, SUPASCHIN JAMJITTRONG, SEIICHI SHINJI, RYO OHTA, HIROMICHI SONODA, TUNYAPORN KAMONVARAPITAK, KUMIKO SEKIGUCHI, MASAO MIYASHITA, HIDEYUKI SUZUKI and HIROSHI YOSHIDA

Anticancer Research June 2020, 40 (6) 3469-3476; DOI: https://doi.org/10.21873/anticanres.14333
You have access
The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents
ONDREJ FIALA, PAVEL OSTASOV, PETR HOSEK, ONDREJ SOREJS, VACLAV LISKA, TOMAS BUCHLER, ALEXANDR POPRACH, RADEK KUCERA, ONDREJ TOPOLCAN, JAN SUSTR, MONIKA SEDIVCOVA and JINDRICH FINEK

Anticancer Research October 2019, 39 (10) 5645-5652; DOI: https://doi.org/10.21873/anticanres.13761
You have access
Relationship Between EGFR Expression in Oral Cancer Cell Lines and Cetuximab Antibody-dependent Cell-mediated Cytotoxicity
HIROSHI NAKAMURA, SHIGEHIRO TAMAKI, TAKAHIRO YAGYUU, NOBUHIRO YAMAKAWA, KATSUHIKO HATAKE and TADAAKI KIRITA

Anticancer Research March 2019, 39 (3) 1275-1282; DOI: https://doi.org/10.21873/anticanres.13238
You have access
Radiolabeling, Characteristics and NanoSPECT/CT Imaging of 188Re-cetuximab in NCI-H292 Human Lung Cancer Xenografts
WAN-I KUO, KAI-HUNG CHENG, YA-JEN CHANG, TSUNG-TSE WU, WEI-CHUAN HSU, LIANG-CHENG CHEN and CHIH-HSIEN CHANG

Anticancer Research January 2019, 39 (1) 183-190; DOI: https://doi.org/10.21873/anticanres.13096
You have access
Phase I Study of Definitive Radio-chemotherapy with Cisplatin, 5-Fluorouracil and Cetuximab for Unresectable Locally Advanced Esophageal Cancer
DIRK RADES, ANNETT MADERER, ANNIKA PANZNER, PETER HUNOLD, VISVAKANTH SIVANATHAN, HEINZ SCHMIDBERGER and MARKUS H. MOEHLER

Anticancer Research May 2017, 37 (5) 2703-2708;
You have access
Amphiregulin as a Novel Resistance Factor for Amrubicin in Lung Cancer Cells
SHUNTARO TOKUNAGA, TATSUYA NAGANO, KAZUYUKI KOBAYASHI, MASAHIRO KATSURADA, KYOSUKE NAKATA, MASATSUGU YAMAMOTO, MOTOKO TACHIHARA, HIROSHI KAMIRYO, HIROSHI YOKOZAKI and YOSHIHIRO NISHIMURA

Anticancer Research May 2017, 37 (5) 2225-2231;
You have access
Cilengitide and Cetuximab Reduce Cytokine Production and Colony Formation of Head and Neck Squamous Cell Carcinoma Cells Ex Vivo
GUNNAR WICHMANN, SUSAN CEDRA, DAPHNE SCHLEGEL, MARLEN KOLB, SUSANNE WIEGAND, ANDREAS BOEHM, MATHIAS HOFER and ANDREAS DIETZ

Anticancer Research February 2017, 37 (2) 521-527;
You have access
Assessment of Pharmacokinetic Interaction Between Capecitabine and Cetuximab in Metastatic Colorectal Cancer Patients
VERONIKA RACHAR, MARTIN CZEJKA, MARIE KITZMUELLER, PHILIPP BUCHNER, MARIA LICHTNECKERT, RICHARD GREIL, HERBERT GEILER and CHRISTIAN DITTRICH

Anticancer Research September 2016, 36 (9) 4715-4723;

Main menu

User menu

Search

cetuximab

Pages